title: Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.
abstract: In Hodgkin lymphoma (HL), the malignant Hodgkin Reed-Sternberg (HRS) cells constitute only 0.5% of 10% of the diseased tissue. The surrounding cellular infiltrate is enriched with T cells that are hypothesized to modulate antitumor immunity. We show that a marker of regulatory T cells, LAG-3, is strongly expressed on infiltrating lymphocytes present in proximity to HRS cells. Circulating regulatory T cells (CD4+ CD25hi CD45 ROhi, CD4+ CTLA4hi, and CD4+ LAG-3hi were elevated in HL patients with active disease when compared with remission. Longitudinal profiling of EBV-specific CD8+ T-cell responses in 94 HL patients revealed a selective loss of interferon-gamma expression by CD8+ T cells specific for latent membrane proteins 1 and 2 (LMP1/2), irrespective of EBV tissue status. Intratumoral LAG-3 expression was associated with EBV tissue positivity, whereas FOXP3 was linked with neither LAG-3 nor EBV tissue status. The level of LAG-3 and FOXP3 expression on the tumor-infiltrating lymphocytes was coincident with impairment of LMP1/2-specific T-cell function. In vitro pre-exposure of peripheral blood mononuclear cells to HRS cell line supernatant significantly increased the expansion of regulatory T cells and suppressed LMP-specific T-cell responses. Deletion of CD4+ LAG-3+ T cells enhanced LMP-specific reactivity. These findings indicate a pivotal role for regulatory T cells and LAG-3 in the suppression of EBV-specific cell-mediated immunity in HL.
authors.affiliation: Tumor Immunology Laboratory, Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Brisbane, Australia.
authors.forename: Maher K
authors.initials: MK
authors.lastname: Gandhi
authors.forename: Eleanore
authors.initials: E
authors.lastname: Lambley
authors.forename: Jaikumar
authors.initials: J
authors.lastname: Duraiswamy
authors.forename: Ujjwal
authors.initials: U
authors.lastname: Dua
authors.forename: Corey
authors.initials: C
authors.lastname: Smith
authors.forename: Suzanne
authors.initials: S
authors.lastname: Elliott
authors.forename: Devinder
authors.initials: D
authors.lastname: Gill
authors.forename: Paula
authors.initials: P
authors.lastname: Marlton
authors.forename: John
authors.initials: J
authors.lastname: Seymour
authors.forename: Rajiv
authors.initials: R
authors.lastname: Khanna
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000096:biosynthesis*; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism / Q000502:physiology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006689:Hodgkin Disease / Q000097:blood* / Q000378:metabolism*; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D014763:Viral Matrix Proteins / Q000378:metabolism*; D000093322:Lymphocyte Activation Gene 3 Protein
chemical_list: D015703:Antigens, CD; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D014763:Viral Matrix Proteins; D000093322:Lymphocyte Activation Gene 3 Protein; C000720326:Lag3 protein, human